Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Depreciation & Amortization (CF) (2017 - 2025)

Historic Depreciation & Amortization (CF) for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $1.9 million.

  • Sutro Biopharma's Depreciation & Amortization (CF) rose 561.42% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 687.76%. This contributed to the annual value of $7.2 million for FY2024, which is 589.79% up from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's Depreciation & Amortization (CF) is $1.9 million, which was up 561.42% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Depreciation & Amortization (CF) registered a high of $1.9 million during Q1 2025, and its lowest value of $1.1 million during Q3 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $1.6 million, with a median of $1.7 million in 2023.
  • Data for Sutro Biopharma's Depreciation & Amortization (CF) shows a peak YoY increase of 2862.25% (in 2022) and a maximum YoY decrease of 278.85% (in 2022) over the last 5 years.
  • Over the past 5 years, Sutro Biopharma's Depreciation & Amortization (CF) (Quarter) stood at $1.3 million in 2021, then grew by 16.96% to $1.5 million in 2022, then increased by 12.55% to $1.7 million in 2023, then grew by 7.91% to $1.9 million in 2024, then rose by 1.71% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.9 million for Q2 2025, and $1.9 million during Q1 2025.